Matching articles for "telaprevir"
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • February 29, 2016; (Issue 1489)
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of...
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection.
A 4-Drug Combination (Viekira Pak) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • February 2, 2015; (Issue 1461)
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged...
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged with
a third new direct-acting antiviral agent (dasabuvir) in
a second tablet, for oral treatment of chronic hepatitis
C virus (HCV) genotype 1 infection. Genotype 1 is
responsible for 70-80% of HCV infections in the US.
Sofosbuvir (Sovaldi) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • January 20, 2014; (Issue 1434)
The FDA has approved the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi – Gilead) for use in
combination with other antiviral drugs for treatment of
chronic hepatitis C virus (HCV)...
The FDA has approved the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi – Gilead) for use in
combination with other antiviral drugs for treatment of
chronic hepatitis C virus (HCV) infection.
Simeprevir (Olysio) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • January 6, 2014; (Issue 1433)
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination...
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir (Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV genotypes, will be reviewed in the next issue of The Medical Letter.
Antiviral Drugs
The Medical Letter on Drugs and Therapeutics • March 1, 2013; (Issue 127)
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.
Drugs for Hepatitis C
The Medical Letter on Drugs and Therapeutics • October 15, 2012; (Issue 1401)
The CDC is now recommending that everyone in the
US born between 1945 and 1965 be tested for hepatitis
C virus (HCV)...
The CDC is now recommending that everyone in the
US born between 1945 and 1965 be tested for hepatitis
C virus (HCV) infection.
Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • July 25, 2011; (Issue 1369)
Telaprevir (Incivek – Vertex) and boceprevir (Victrelis –
Merck) have been approved by the FDA for oral use in
combination with peginterferon and ribavirin for treatment
of chronic hepatitis C virus...
Telaprevir (Incivek – Vertex) and boceprevir (Victrelis –
Merck) have been approved by the FDA for oral use in
combination with peginterferon and ribavirin for treatment
of chronic hepatitis C virus (HCV) genotype 1
infection in adults with compensated liver disease.
Both telaprevir and boceprevir were developed specifically
to inhibit the NS3/4A proteases that cleave HCV
encoded polyproteins of the genotype 1 virus.